Edwards Lifesciences highlights valve trial data, shares ahead of July earnings

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 11:06.

Edwards Lifesciences (US28176E1082) has drawn fresh attention after presenting new clinical data on its transcatheter valve portfolio at the New York Valves 2026 conference, while its shares trade on the NYSE ahead of the next earnings update. Analysts now anchor their near-term view on the July 23 earnings date and the latest consensus numbers.

What the New York data showed

According to a June 26 note, Edwards Lifesciences presented trial data at the New York Valves conference, with a focus on the PROGRESS, EARLY TAVR and PARTNER 3 studies on the SAPIEN platform. A Simply Wall St summary highlights that the company used the meeting to showcase extensive clinical results supporting transcatheter aortic valve replacement in broader patient groups, drawing renewed investor interest. The SAPIEN-based trials are central to Edwards Lifesciences' growth narrative in structural heart therapies and provide evidence for potential expansion of indications in a competitive field that includes Medtronic.

Consensus ahead of July earnings

MarketBeat data show that Edwards Lifesciences is scheduled to report its next quarterly figures for the second quarter of 2026 on July 23 after the market closes, which is the current anchor date for Wall Street coverage. For that release, the consensus estimate for earnings per share stands at around 0.73 dollars, compared with the actual EPS of 0.78 dollars reported on April 23, when the company beat expectations by roughly 0.05 dollars. The same source notes that Edwards Lifesciences generated revenue of about 1.6 billion dollars in the April quarter, underpinning its position as a mid-cap healthcare name within the S&P 500 and setting the baseline for analysts' forward models.

The product behind the stock

Edwards Lifesciences generates a large share of its revenue from transcatheter heart valve therapies, led by the SAPIEN transcatheter aortic valve system used to treat severe symptomatic aortic stenosis in patients at various surgical risk levels, supported by data from trials such as PARTNER 3. Beyond TAVR, the company also develops minimally invasive structural heart solutions for mitral and tricuspid valve disease and monitoring technologies for critical care, forming a focused cardiovascular-device portfolio.

Where the shares trade today

Edwards Lifesciences shares (US28176E1082) last closed on June 26, 2026 at 90.81 dollars on the NYSE, with indicative extended-hours trading at about 92.25 dollars per share on the same day.

This text is for informational purposes only and does not constitute investment advice, tax advice or a solicitation to buy or sell securities. Figures and dates are based on sources cited in the text and may change over time.